1981Acta PaediatricaRequires access

PROPHYLAXIS AGAINST FEBRILE CONVULSIONS WITH PHENOBARBITAL

S. Pilgaard, Flemming Juul Hansen, P. PÆGAARD

Open publisher page 9 citations

Abstract

Abstract. Pilgaard, S., Hansen, F. J. and Paerregaard, P. (Department of Paediatrics, Sundby Hospital, Copenhagen, Denmark). Prophylaxis against febrile convulsions with phenobarbital. Acta Paediatr Scand, 70:67, 1981. An unselected patient material of 182 children admitted consecutively with febrile convulsions during a period of two years was classified into five risk‐groups. Continuous phenobarbital therapy for two years was recommended for 113 children (Groups I‐IV). These children were followed‐up as outpatients for at least one year after admission. In children receiving phenobarbital therapy, serum concentrations were controlled every third month. A total of 59 children completed the treatment according to the directives given and seven of these (12%) developed renewed febrile convulsions despite serum phenobarbital concentrations within the therapeutic range (70–120 µmol/l). No particular characteristics for these children could be established on the basis of the parameters registered. The therapeutic model established was found to be suitable for distinguishing between children with massive risk for renewed convulsions (Groups I‐IV) compared with children for whom treatment was not recommended (Group V).

About this research paper

What this paper is about

Abstract. Pilgaard, S., Hansen, F. J. and Paerregaard, P. (Department of Paediatrics, Sundby Hospital, Copenhagen, Denmark). Prophylaxis against febrile convulsions with phenobarbital. Acta Paediatr Scand, 70:67, 1981. An unselected patient material of 182 children admitted consecutively with febrile convulsions during a period of two years was classified into five risk‐groups. Continuous phenobarbital therapy for two years was recommended for 113 children (Groups I‐IV). These children were followed‐up as outpatients for at least one year after admission. In children receiving phenobarbital therapy, serum concentrations were controlled every third month. A total of 59 children completed the treatment according to the directives given and seven of these (12%) developed renewed febrile convulsions despite serum phenobarbital concentrations within the therapeutic range (70–120 µmol/l). No particular characteristics for these children could be established on the basis of the parameters registered. The therapeutic model established was found to be suitable for distinguishing between children with massive risk for renewed convulsions (Groups I‐IV) compared with children for whom treatment was not recommended (Group V).

Why it matters

OpenAlex reports 9 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Abstract. Pilgaard, S., Hansen, F. J. and Paerregaard, P. (Department of Paediatrics, Sundby Hospital, Copenhagen, Denmark). Prophylaxis against febrile convulsions with phenobarbital. Acta Paediatr Scand, 70:67, 1981. An unselected patient material of 182 children admitted consecutively with febrile convulsions during a period of two years was classified into five risk‐groups. Continuous phenobarbital therapy for two years was recommended for 113 children (Groups I‐IV). These children were followed‐up as outpatients for at least one year after admission. In children receiving phenobarbital therapy, serum concentrations were controlled every third month. A total of 59 children completed the treatment according to the directives given and seven of these (12%) developed renewed febrile convulsions despite serum phenobarbital concentrations within the therapeutic range (70–120 µmol/l). No particular characteristics for these children could be established on the basis of the parameters registered. The therapeutic model established was found to be suitable for distinguishing between children with massive risk for renewed convulsions (Groups I‐IV) compared with children for whom treatment was not recommended (Group V).

Key concepts: Phenobarbital, Medicine, Febrile convulsions, Pediatrics, Therapeutic index, Febrile seizure, Anesthesia, Epilepsy

Related papers

Back to paper searchBrowse research topicsOriginal source
PROPHYLAXIS AGAINST FEBRILE CONVULSIONS WITH PHENOBARBITAL — Research Paper | ScholarLens